Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Core Insights - Vor Bio has appointed Alexander (Bo) Cumbo and Michel Detheux, Ph.D., to its Board of Directors, bringing extensive experience in company building, corporate strategy, and commercialization [1][4]. Group 1: New Board Members - Alexander (Bo) Cumbo has over 30 years of commercial and executive leadership experience, including roles at Solid Biosciences and Sarepta Therapeutics, where he was instrumental in launching multiple rare disease therapies [2]. - Michel Detheux, Ph.D., co-founded iTeos Therapeutics and led it through significant capital raises and a partnership with GSK worth $2 billion for co-developing an anti-TIGIT antibody [3]. Group 2: Company Vision and Strategy - The new board members are expected to provide valuable insights as Vor Bio advances its lead product, telitacicept, through late-stage development and aims to become a leader in autoimmune innovation [4]. - Vor Bio is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development to address serious autoantibody-driven conditions globally [5].